Spots Global Cancer Trial Database for bladder
Every month we try and update this database with for bladder cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer | NCT00918008 | Bladder Cancer | Blood draw | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma | NCT00714948 | Bladder Cancer URINARY BLADDER | gemcitabine and... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection | NCT00816075 | Recurrent Super... Distilled Water | distilled water | - | Bozyaka Training and Research Hospital | |
| Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection | NCT02852564 | Bladder Cancer | Ethacrynic Acid | 18 Years - | University of Kansas Medical Center | |
| Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection | NCT00816075 | Recurrent Super... Distilled Water | distilled water | - | Bozyaka Training and Research Hospital | |
| Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder | NCT02202772 | Urothelial Carc... | Cabazitaxel Gemcitabine Cisplatin | 18 Years - | Columbia University | |
| Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma | NCT00714948 | Bladder Cancer URINARY BLADDER | gemcitabine and... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy | NCT01827618 | Invasive Bladde... | Rapamycin | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Randomized Trial Comparing Robotic and Open Radical Cystectomy | NCT01076387 | Bladder Cancer | open radical cy... robotic-assiste... | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | NCT00722553 | Carcinoma, Tran... Bladder Cancer Bladder Neoplas... | Pralatrexate In... Vitamin B12 Folic Acid | 18 Years - | Acrotech Biopharma Inc. | |
| Neoadjuvant Atezolizumab in Localized Bladder Cancer | NCT02451423 | Carcinoma, Tran... | Atezolizumab | 18 Years - | University of California, San Francisco | |
| Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | NCT03836352 | Ovarian Cancer Hepatocellular ... Non-small Cell ... Bladder Cancer Microsatellite ... | DPX-Survivac Cyclophosphamid... Pembrolizumab | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| Randomized Trial Comparing Robotic and Open Radical Cystectomy | NCT01076387 | Bladder Cancer | open radical cy... robotic-assiste... | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance | NCT05796375 | Non-muscle-inva... | Cystoscopy Bladder EpiChec... Xpert Bladder C... | 18 Years - | White River Junction Veterans Affairs Medical Center | |
| Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder | NCT00963859 | Bladder Cancer | Robotic-assiste... | - | M.D. Anderson Cancer Center | |
| Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer | NCT01700010 | Urothelial Canc... Bladder Cancer | Lapatinib and P... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma | NCT01261728 | Urothelial Carc... | Gemcitabine and... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222 | Urothelial Carc... | DN24-02 Standard of Car... | 18 Years - | Dendreon | |
| Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test. | NCT04647981 | Non-Invasive Bl... Non-Invasive Bl... Non-Invasive Bl... | Xpert® Bladder ... | 18 Years - | Clinique Beau Soleil | |
| Development of Diagnostics and Treatment of Urological Cancers | NCT02994758 | Prostate Carcin... Kidney Cancer Urothelial Carc... Testicular Canc... Penile Cancer | Personalised tr... | 18 Years - | Helsinki University Central Hospital | |
| Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | NCT02300610 | Bladder Cancer Carcinoma, Tran... Renal Pelvis Ca... Ureter Cancer Urethra Cancer | Enzalutamide Cisplatin Gemcitabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | NCT02030067 | Solid Tumor Metastatic Blad... | RX-3117 | 18 Years - | Processa Pharmaceuticals | |
| Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder | NCT02723838 | Muscle-invasive... | REOLYSIN® Gemcitabine Cisplatin | 18 Years - | Oncolytics Biotech | |
| A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer | NCT01454089 | Urologic Neopla... Metastatic Blad... Urinary Tract N... | OGX-427 600 mg OGX-427 1000 mg Placebo Gemcitabine Cisplatin Carboplatin | 18 Years - | Achieve Life Sciences | |
| A Genotype-Phenotype Urothelial Cancer Registry | NCT00902590 | Urothelial Canc... Renal Pelvis Ca... Ureter Cancer Bladder Cancer | saliva sample a... saliva sample, ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study | NCT03832673 | Muscle-invasive... | Pembrolizumab Epacadostat | 18 Years - 99 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer | NCT00237575 | Bladder Cancer | gemcitabine cisplatin sargramostim filgrastim | 18 Years - | University of Kentucky | |
| A Study Using MRI To Assess Bladder Motion During Radiotherapy | NCT03409029 | Bladder Cancer | MRI Scan | 18 Years - | The Christie NHS Foundation Trust | |
| Urine Cytology and Utility in Bladder Recurrence | NCT00971256 | Bladder Cancer | 18 Years - | William Beaumont Hospitals | ||
| Dose Dense MVAC for Muscle Invasive Bladder Cancer | NCT01031420 | Muscle Invasive... High Risk Uroth... | single arm dose... | 18 Years - | Fox Chase Cancer Center | |
| A Genotype-Phenotype Urothelial Cancer Registry | NCT00902590 | Urothelial Canc... Renal Pelvis Ca... Ureter Cancer Bladder Cancer | saliva sample a... saliva sample, ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium | NCT00756639 | Bladder Cancer | Prophylactic Cr... Brain X-ray | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03170960 | Urothelial Carc... Renal Cell Carc... Non-Small Cell ... Castration-resi... Triple Negative... Ovarian Cancer Endometrial Can... Hepatocellular ... Gastric Cancer Gastroesophagea... Colorectal Canc... Head and Neck C... Differentiated ... Lower Esophagea... | cabozantinib atezolizumab cabozantinib cabozantinib | 18 Years - | Exelixis | |
| Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | NCT03633110 | Cutaneous Melan... Non-small Cell ... Squamous Cell C... Urothelial Carc... Renal Cell Carc... | GEN-009 Adjuvan... Nivolumab Pembrolizumab | 18 Years - | Genocea Biosciences, Inc. | |
| Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer | NCT00237575 | Bladder Cancer | gemcitabine cisplatin sargramostim filgrastim | 18 Years - | University of Kentucky | |
| A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer | NCT01454089 | Urologic Neopla... Metastatic Blad... Urinary Tract N... | OGX-427 600 mg OGX-427 1000 mg Placebo Gemcitabine Cisplatin Carboplatin | 18 Years - | Achieve Life Sciences | |
| Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium | NCT00756639 | Bladder Cancer | Prophylactic Cr... Brain X-ray | 18 Years - | M.D. Anderson Cancer Center | |
| Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent | NCT00544609 | Bladder Cancer | Sorafenib Radiotherapy | 18 Years - | Spanish Oncology Genito-Urinary Group | |
| Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) | NCT01663285 | Urothelial Canc... Bladder Cancer | Neoadjuvant Cis... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Intravesical Thermochemotherapy With Mitomycin-c | NCT03694535 | Bladder Cancer | bladder wall th... | - | TC Erciyes University | |
| Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors | NCT02257476 | Neoplasms Malignancies | Carfilzomib Dexamethasone | 18 Years - | Emory University | |
| Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer | NCT00634621 | Bladder Cancer | Hexaminolevulin... | 18 Years - | GE Healthcare | |
| CONFIRM: Magnetic Resonance Guided Radiation Therapy | NCT04368702 | Gastric Cancer Invasive Breast... in Situ Breast ... Mantle Cell Lym... Larynx Cancer Bladder Cancer | Viewray MRIdian... | 18 Years - | Dana-Farber Cancer Institute | |
| Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | NCT00847015 | Bladder Cancer Urinary Bladder | Sunitinib Gemcitabine cisplatin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium | NCT00756639 | Bladder Cancer | Prophylactic Cr... Brain X-ray | 18 Years - | M.D. Anderson Cancer Center | |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222 | Urothelial Carc... | DN24-02 Standard of Car... | 18 Years - | Dendreon | |
| Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder | NCT02723838 | Muscle-invasive... | REOLYSIN® Gemcitabine Cisplatin | 18 Years - | Oncolytics Biotech | |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | NCT03132922 | Urinary Bladder... Melanoma Head and Neck C... Ovarian Cancer Non-Small Cell ... Esophageal Canc... Gastric Cancer Synovial Sarcom... Myxoid Round Ce... Gastroesophagea... | Autologous gene... Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| A Study Using MRI To Assess Bladder Motion During Radiotherapy | NCT03409029 | Bladder Cancer | MRI Scan | 18 Years - | The Christie NHS Foundation Trust | |
| A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT | NCT02010203 | Bladder Cancer | HS-410 Placebo BCG | 18 Years - | Heat Biologics | |
| Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | NCT00722553 | Carcinoma, Tran... Bladder Cancer Bladder Neoplas... | Pralatrexate In... Vitamin B12 Folic Acid | 18 Years - | Acrotech Biopharma Inc. | |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer | NCT03759496 | Bladder Cancer | Durvalumab | 18 Years - | Hellenic GenitoUrinary Cancer Group | |
| Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | NCT02300610 | Bladder Cancer Carcinoma, Tran... Renal Pelvis Ca... Ureter Cancer Urethra Cancer | Enzalutamide Cisplatin Gemcitabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Development of Diagnostics and Treatment of Urological Cancers | NCT02994758 | Prostate Carcin... Kidney Cancer Urothelial Carc... Testicular Canc... Penile Cancer | Personalised tr... | 18 Years - | Helsinki University Central Hospital | |
| Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC | NCT04610671 | Muscle-Invasive... Bladder Cancer | CG0070 Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer | NCT03785925 | Urinary Bladder... Neoplasm Metast... | Bempegaldesleuk... Nivolumab | 18 Years - | Nektar Therapeutics | |
| A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT | NCT02010203 | Bladder Cancer | HS-410 Placebo BCG | 18 Years - | Heat Biologics | |
| Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | NCT03740256 | Bladder Cancer Head and Neck S... Cancer of the S... Lung Cancer Breast Cancer Gastric Cancer Esophageal Canc... Colorectal Canc... Pancreatic Aden... Solid Tumor | CAdVEC | 18 Years - | Baylor College of Medicine | |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | NCT04596033 | Melanoma Non-small Cell ... Squamous Cell C... Urothelial Carc... Renal Cell Carc... Small-cell Lung... Cutaneous Squam... Anal Squamous C... Merkel Cell Car... | GEN-011 IL-2 Fludarabine Cyclophosphamid... | 18 Years - | Genocea Biosciences, Inc. | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | NCT03132922 | Urinary Bladder... Melanoma Head and Neck C... Ovarian Cancer Non-Small Cell ... Esophageal Canc... Gastric Cancer Synovial Sarcom... Myxoid Round Ce... Gastroesophagea... | Autologous gene... Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer | NCT03759496 | Bladder Cancer | Durvalumab | 18 Years - | Hellenic GenitoUrinary Cancer Group | |
| Feasibility of Online Adaptive Radiotherapy for Muscle Invasive Bladder Cancer | NCT01142102 | Bladder Cancer | Radiation Thera... | 18 Years - | Trans Tasman Radiation Oncology Group | |
| Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance | NCT05796375 | Non-muscle-inva... | Cystoscopy Bladder EpiChec... Xpert Bladder C... | 18 Years - | White River Junction Veterans Affairs Medical Center | |
| Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | NCT02030067 | Solid Tumor Metastatic Blad... | RX-3117 | 18 Years - | Processa Pharmaceuticals | |
| Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection | NCT02852564 | Bladder Cancer | Ethacrynic Acid | 18 Years - | University of Kansas Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
